399
Participants
Start Date
September 24, 2021
Primary Completion Date
January 10, 2024
Study Completion Date
January 10, 2024
X0002
Subjects will complete 22 weeks of double-blind treatment and then enter into 30 weeks open-label treatment.
Upstate Clinical Research Associates LLC, Williamsville
Altoona Center For Clinical Research, Duncansville
Charlottesville Medical Research, LLC, Charlottesville
Spectrum Medical, Inc, Danville
Horizon Clinical Research, Newnan
Pinnacle Trials Inc, Stockbridge
University Clinical Research-Deland, DeLand
Conquest Research, Winter Park
Reliable Clinical Research, Hialeah
Health Awareness Inc., Jupiter
Ascension Research, Pinellas Park
DelRicht Research - Gulfport, Gulfport
Aventiv Research, Inc - Brice Road Location, Columbus
Healthcare Research Network, Flossmoor
Affinity Health Corp, Oak Brook
Chicago Clinical Research Institute Inc, Chicago
Northwestern University, Chicago
Healthcare Research Network, LLC, Hazelwood
Sundance Clinical Research, LLC, St Louis
AMR Kansas City, Kansas City
DelRicht Research, New Orleans
DelRicht Research, Prairieville
DelRicht Research, Tulsa
Clinical Investigations of Texas, Plano
Quality Research Inc., San Antonio
Tekton Research, Austin
Wasatch Clinical Research LLC, Salt Lake City
Arizona Research Center, Phoenix
Yuma Clinical Trials, Yuma
AMR: Las Vegas, Las Vegas
Velocity Clinical Research, North Hollywood
Biosolutions Clinical Research Center, La Mesa
Orange County Research Institute, Anaheim
Techfields Pharma Co. Ltd
INDUSTRY